Focus on Productivity Driving Biopharma: New, 2012 study finds demand for productivity is a key fact

Since the recent economic downturn, we have seen a rapid maturation and reshaping of biomanufacturing strategy. According to the just released 9th Annual Report and Survey of Biopharmaceutical Manufacturing from BioPlan Associates, Inc, among the 15 areas creating improvements in bioprocessing, the majority of the 302 global respondents this year indicated that their greatest performance increases were stemming from areas associated with productivity, including: better process control, improved up- and downstream operations, better process development, and better operations staff training.  In addition, of the 229 data graphs and tables, many of the report’s findings pointed to productivity, even over cost-cutting, as the strategic focus going forward.

Even in areas such as outsourcing, budgets actually declined this year unless the areas were explicitly related to improved productivity.  In areas such as global outsourcing as well, where we asked which country would be a top outsourcing destination within the next five years, because of perceptions of improvements in certain aspects of bioprocessing, China topped the list again this year, followed by India at 18.4%, with Germany rounding the top three choices at 16.7% as future ‘potential’ outsourcing destinations for biomanufacturing.

Among the 1000s of findings, many related to productivity including:

  • 6.4% increase in budgets for new downstream technologies
  • 14.4% outsourced jobs in manufacturing
  • 19.2%: Average sales growth rate for CMOs to biomanufacturing
  • 50.7% seeking to hire better process development staff
  • 96.8% demanding better working relationships from their CMOs
  • 47.2% Evaluating better-performing membrane filtration technologies
  • 46.2% Using disposables to eliminate cleaning
  • 66.0% of Europeans improved their downstream operations
  • 66.8% Focused on cost-cutting, down significantly from 2011
  • China is NOW the #1 outsourcing destination for US companies
  • 20% improvement in time between batch failures
  • Average MAB titer up 9% since 2008
  • 17.4% to expand mammalian cell production more than 100% within 5 years
  • 49% auditing their vendors more frequently
  • 50% of vendors expect to do better in 2012

The 9th Annual Report and Survey of Biopharmaceutical Manufacturing contains global analysis of 302 biomanufacturers and 185 suppliers in 29 countries, includes with analysis from 12 industry experts. The 471 page study is the industry’s definitive, quantitative analysis and includes nearly a decade of biopharma trends and opportunities. The Report covers 12 critical areas, including: industry growth, downstream processing, single use systems, outsourcing, capacity, and quality management and much more!  All detailed with input and commentary from industry experts.

This study features trends including biosimilars and outsourcing that are opening opportunities and challenges to the entire industry. The study also compares over time how European, U.S., and Asian biomanufacturers differ in demands for new technologies. Innovation has never been better funded and broad in scope.

Global capacity data show the impact of biosimilars and outsourcing, as well as downstream processing and single-use devices, and how they are creating growth potential in both capacity and in the number of facilities coming on-line. This will affect:

  • Overall industry growth
  • Opportunities for suppliers to the industry
  • Demand for skilled staff and better technology
  • Regulatory demands on the industry

We compare how European, U.S., and Asian biomanufacturers differ in demands for new technologies, budgets, outsourcing and much more. Innovation has never been better funded. Find out where, and what’s in the new product pipeline!  Compare 302 biotherapeutic developers vs CMOs; US vs European & Global Biomanufacturing.

References:  9th Annual Report and Survey of Biopharmaceutical Manufacturing, April 2012, 471 Pages, See:

Contributions by Eric S. Langer, President and Managing Partner, BioPlan Associates, Inc